Formulation Licenses
Registered finished dosage forms (FDF), transferable tech packages and in-development in-licensing pipelines · delivered per target-market approval pathway
Formulation (FDF)
Nalmefene Hydrochloride nasal spray
— · 3mg/spray, 0.1ml
- Therapy
- Anesthesiology
- Status
- Official FDF licensing catalog (UB534)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Midazolam Nasal Spray
— · 5mg/Spray, 0.1ml
- Therapy
- Neurology
- Status
- Official FDF licensing catalog (UB533)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Diazepam Nasal Spray
— · 10mg/Spray, 0.1ml
- Therapy
- Neurology
- Status
- Official FDF licensing catalog (UB532)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Cyanocobalamin (Vitamin B12) Nasal Spray
— · 0.5mg/0.1mL
- Therapy
- Others > Hematology
- Status
- Official FDF licensing catalog (UB531)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Naloxone hydrochloride nasal spray
— · 4mg/ Spray, 0.1ml
- Therapy
- Anesthesiology
- Status
- Official FDF licensing catalog (UB530)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Droperidol Injection
Injection · 2ml/5mg
- Therapy
- Others > Psychiatry
- Status
- Official FDF licensing catalog (UB529)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Epinephrine injection
injection · 1mg:1mL
- Therapy
- Others > Critical Care
- Status
- Official FDF licensing catalog (UB528)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Methylene blue Injection
Injection · 50mg/10mL
- Therapy
- Others > Hematology
- Status
- Official FDF licensing catalog (UB527)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Nicardipine Hydrochloride Injection
Injection · 25mg/10mL(2.5mg/mL)
- Therapy
- Cardiovascular
- Status
- Official FDF licensing catalog (UB526)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Nalmefene Hydrochloride Injection
Injection · 2mg/2mL (1mg/mL)
- Therapy
- Anesthesiology
- Status
- Official FDF licensing catalog (UB525)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Topiramate Sustained-Release Capsule
Capsule
- Therapy
- Neurology
- Status
- Official FDF licensing catalog (UB517)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States, China
Formulation (FDF)
Memantine Hydrochloride and Donepezil Hydrochloride Sustained-Release Capsule
Capsule
- Therapy
- Neurology
- Status
- Official FDF licensing catalog (UB516)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States, China
Formulation (FDF)
Memantine Hydrochloride Sustained-release Capsules
Capsules · 28mg
- Therapy
- Neurology
- Status
- Official FDF licensing catalog (UB515)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States, China
Formulation (FDF)
IV Human Immunoglobulin (pH4) for Intravenous Injection
Injection · 1.25mg, 2.5mg, 5mg
- Therapy
- Immunology & Inflammation
- Status
- Official FDF licensing catalog (UB514)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Visepegenatide Injection
Injection
- Therapy
- Metabolic & Endocrinology
- Status
- Official FDF licensing catalog (UB513)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Aripiprazole Oral Solution Film
Oral Solution · 5mg, 10mg
- Therapy
- Others > Psychiatry
- Status
- Official FDF licensing catalog (UB512)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States, China
Formulation (FDF)
Pramipexole Dihydrochloride Sustained-Release Tablet
Tablet · 0.375, 0.75mg
- Therapy
- Neurology
- Status
- Official FDF licensing catalog (UB511)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States, China
Formulation (FDF)
Clonidine Hydrochloride Sustained-Release Tablet
Tablet · 0.1mg
- Therapy
- Others > Psychiatry
- Status
- Official FDF licensing catalog (UB510)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States, China
Formulation (FDF)
dried amniotic membrane
—
- Therapy
- Others > Dermatology
- Status
- Official FDF licensing catalog (UB508)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- Japan
Formulation (FDF)
Carbetocin Injection
Injection · 100 mcg/1 mL
- Therapy
- Others > Women's Health
- Status
- Official FDF licensing catalog (UB507)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Desmopressin Acetate Tablets
Tablets · 0.1 mg; 0.2 mg
- Therapy
- Nephrology & Urology
- Status
- Official FDF licensing catalog (UB506)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Desmopressin Acetate Injection
Injection · 1 ml: 4 μg; 1 ml: 15 μg
- Therapy
- Nephrology & Urology
- Status
- Official FDF licensing catalog (UB505)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Octreotide Acetate Injection
Injection · (1)1 ml:0.05 mg (2)1ml:0.1mg (3)1ml:0.3mg
- Therapy
- Metabolic & Endocrinology
- Status
- Official FDF licensing catalog (UB504)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Entecavir
— · 0.5mg
- Therapy
- Gastroenterology & Hepatology
- Status
- Official FDF licensing catalog (UB503)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Atosiban
— · 0.9 ml:6.75mg; 5 ml:37.5 mg
- Therapy
- Others > Women's Health
- Status
- Official FDF licensing catalog (UB502)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Thymalfasin Injection
Injection · 1.6 mg
- Therapy
- Immunology & Inflammation
- Status
- Official FDF licensing catalog (UB501)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Thymopentin Injection
Injection · (1)1 mg,10 mg (Thymopentin for injection);(2)1 ml:1 mg,1 ml:10 mg(Thymopentin injection);(3)1 ml:1mg,1 ml:10 mg(Thymopentin prefilled injection)
- Therapy
- Immunology & Inflammation
- Status
- Official FDF licensing catalog (UB500)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Trastuzumab
— · 150mg/vial
- Therapy
- Oncology
- Status
- Official FDF licensing catalog (UB492)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Recombinant Human Interferon α2b
— · Injection, Eyedrop, Suppository, Cream
- Therapy
- Infectious Diseases
- Status
- Official FDF licensing catalog (UB491)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Recombinant Human Growth Hormone
— · 2IU, 4IU, 4.5IU, 6IU, 8IU, 10IU, 16IU
- Therapy
- Metabolic & Endocrinology
- Status
- Official FDF licensing catalog (UB490)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Desloratadine Oral Suspension
Suspension · 2.5mg,5mg
- Therapy
- Immunology & Inflammation
- Status
- Official FDF licensing catalog (UB489)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- EU
Formulation (FDF)
Desloratadine Tablet
Tablet · 5mg
- Therapy
- Immunology & Inflammation
- Status
- Official FDF licensing catalog (UB488)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- EU
Formulation (FDF)
Bivalirudin Injection
Injection · 250mg
- Therapy
- Cardiovascular
- Status
- Official FDF licensing catalog (UB487)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States, EU
Formulation (FDF)
Eptifibatide Injection
Injection · 20mg/10ml; 75mg/100ml
- Therapy
- Cardiovascular
- Status
- Official FDF licensing catalog (UB486)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States, EU, Saudi Arabia
Formulation (FDF)
Methocarbamol Injection
Injection · 1g/10ml (100mg/ml)
- Therapy
- Anesthesiology
- Status
- Official FDF licensing catalog (UB485)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Cisatracurium Besylate Injection
Injection · 10mg/5ml; 20mg/10ml; 200mg/20ml
- Therapy
- Anesthesiology
- Status
- Official FDF licensing catalog (UB484)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Cyclophosphamide Injection
Injection · 500mg, 1g, 2g
- Therapy
- Oncology
- Status
- Official FDF licensing catalog (UB483)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Carfilzomib for Injection
for Injection · 60mg
- Therapy
- Oncology
- Status
- Official FDF licensing catalog (UB482)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Levoleucovorin Calcium Injection
Injection · 175mg/17.5ml, 250mg/25ml
- Therapy
- Oncology
- Status
- Official FDF licensing catalog (UB481)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Leucovorin Calcium Injection
Injection · 50mg,100mg, 200mg,350mg,500mg
- Therapy
- Oncology
- Status
- Official FDF licensing catalog (UB480)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States, Saudi Arabia
Formulation (FDF)
Nitroprusside in 0.9% NaCl Infusion
— · 10mg/50ml, 20mg/100ml, 50mg/100ml U
- Therapy
- Cardiovascular
- Status
- Official FDF licensing catalog (UB479)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Phenylephrine Hydrochloride Injection
Injection · 10mg/1ml, 50mg/5ml, 100mg/10ml
- Therapy
- Cardiovascular
- Status
- Official FDF licensing catalog (UB478)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Dobutamine Injection
Injection · 250mg/20ml, 500mg/40ml
- Therapy
- Cardiovascular
- Status
- Official FDF licensing catalog (UB477)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Amiodarone Hydrochloride Injection
Injection · 150mg/3mL, 450mg/9mL, 900mg/18mL
- Therapy
- Cardiovascular
- Status
- Official FDF licensing catalog (UB476)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Sodium Nitroprusside Injection
Injection · 50mg:2ml
- Therapy
- Cardiovascular
- Status
- Official FDF licensing catalog (UB475)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- EU, United States
Formulation (FDF)
Trimebutine Maleate Tablet
Tablet · 100mg,200mg
- Therapy
- Gastroenterology & Hepatology
- Status
- Official FDF licensing catalog (UB474)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- Canada
Formulation (FDF)
Dicyclomine Hydrochloride Injection
Injection · 20mg/2ml
- Therapy
- Gastroenterology & Hepatology
- Status
- Official FDF licensing catalog (UB473)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Esomeprazole Injection
Injection · 40mg
- Therapy
- Gastroenterology & Hepatology
- Status
- Official FDF licensing catalog (UB472)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- EU, United States